MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients
AbstractMetastatic testicular germ cell tumors (TGCTs) are a potentially curable disease by administration of risk-adapted cytotoxic chemotherapy. Nevertheless, a disease-relapse after curative chemotherapy needs more intensive salvage chemotherapy and significantly worsens the prognosis of TGCT patients. Circulating tumor markers (β-subunit of human chorionic gonadotropin (β-HCG), alpha-Fetoprotein (AFP), and Lactate Dehydrogenase (LDH)) are frequently used for monitoring disease recurrence in TGCT patients, though they lack diagnostic sensitivity and specificity. Increasing evidence suggests that serum levels of stem cell-associated microRNAs (miR-371a-3p and miR-302/367 cluster) are outperforming the traditional tumor markers in terms of sensitivity to detect newly diagnosed TGCT patients. The aim of this study was to investigate whether these miRNAs are also informative in detection of disease recurrence in TGCT patients after curative first line therapy. For this purpose, we measured the serum levels of miR-371a-3p and miR-367 in 52 samples of ten TGCT patients at different time points during disease relapse and during salvage chemotherapy. In our study, miR-371a-3p levels in serum samples with proven disease recurrence were 13.65 fold higher than levels from the same patients without evidence of disease (p = 0.014). In contrast, miR-367 levels were not different in these patient groups (p = 0.985). In conclusion, miR-371a-3p is a sensitive and potentially novel biomarker for detecting disease relapse in TGCT patients. This promising biomarker should be investigated in further large prospective trials. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 337 KB)
Share & Cite This Article
Terbuch, A.; Adiprasito, J.B.; Stiegelbauer, V.; Seles, M.; Klec, C.; Pichler, G.P.; Resel, M.; Posch, F.; Lembeck, A.L.; Stöger, H.; Szkandera, J.; Pummer, K.; Bauernhofer, T.; Hutterer, G.C.; Gerger, A.; Stotz, M.; Pichler, M. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. Int. J. Mol. Sci. 2018, 19, 3130.
Terbuch A, Adiprasito JB, Stiegelbauer V, Seles M, Klec C, Pichler GP, Resel M, Posch F, Lembeck AL, Stöger H, Szkandera J, Pummer K, Bauernhofer T, Hutterer GC, Gerger A, Stotz M, Pichler M. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. International Journal of Molecular Sciences. 2018; 19(10):3130.Chicago/Turabian Style
Terbuch, Angelika; Adiprasito, Jan B.; Stiegelbauer, Verena; Seles, Maximilian; Klec, Christiane; Pichler, Georg P.; Resel, Margit; Posch, Florian; Lembeck, Anna L.; Stöger, Herbert; Szkandera, Joanna; Pummer, Karl; Bauernhofer, Thomas; Hutterer, Georg C.; Gerger, Armin; Stotz, Michael; Pichler, Martin. 2018. "MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients." Int. J. Mol. Sci. 19, no. 10: 3130.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.